Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Epidemiol Sante Publique ; 65(4): 321-325, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28576381

ABSTRACT

BACKGROUND: Quality of coding to identify cancers and comorbidities through the French hospital diagnosis database (Programme de médicalisation des systèmes d'information, PMSI) has been little investigated. Agreement between medical records and PMSI database was evaluated regarding metastatic colorectal cancer (mCRC) and comorbidities. METHODS: From 01/01/2013 to 06/30/2014, 74 patients aged≥65years at mCRC diagnosis were identified in Bordeaux teaching hospital. Data on mCRC and comorbidities were collected from medical records. All diagnosis codes (main, related and associated) registered into the PMSI were extracted. Agreement between sources was evaluated using the percent agreement for mCRC and the kappa (κ) statistic for comorbidities. RESULTS: Agreement for primary CRC and mCRC was higher using all types of diagnosis codes instead of the main one exclusively (respectively 95% vs. 53% for primary CRC and 91% vs. 24% for mCRC). Agreement was substantial (κ 0.65) for cardiovascular diseases, notably atrial fibrillation (κ 0.77) and hypertension (κ 0.68). It was moderate for psychiatric disorders (κ 0.49) and respiratory diseases (κ 0.48), although chronic obstructive pulmonary disease had a good agreement (κ 0.75). Within the class of endocrine, nutritional and metabolic diseases (κ 0.55), agreement was substantial for diabetes (κ 0.91), obesity (κ 0.82) and hypothyroidism (κ 0.72) and moderate for hypercholesterolemia (κ 0.51) and malnutrition (κ 0.42). CONCLUSION: These results are reassuring with regard to detection through PMSI of mCRC if all types of diagnosis codes are considered and useful to better choose comorbidities in elderly mCRC patients that could be well identified through hospital diagnosis codes.


Subject(s)
Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Databases, Factual/standards , International Classification of Diseases , Medical Records/standards , Patient Discharge , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Comorbidity , Female , France/epidemiology , Humans , Male , Neoplasm Metastasis , Patient Discharge/statistics & numerical data
2.
Mol Membr Biol ; 16(2): 157-65, 1999.
Article in English | MEDLINE | ID: mdl-10417980

ABSTRACT

Flavonoids are ubiquitous polyphenolic compounds, found in vascular plants, which are endowed with a large variety of biological effects. Some of these effects have been assumed to result from interactions with the cell plasma membrane. In order to investigate the nature of these interactions a fluorescence study was performed with two flavonoids, currently used in one of the laboratories: apigenin and its homologous dimer amentoflavone. After preliminary assays with DPH in several types of phospholipid liposomes, the effects of these flavonoids on the membrane of mouse L929 fibroblasts were compared, using the non-permeant probe TMA-DPH. Amentoflavone, unlike apigenin, induced a static quenching effect, which denoted an important, but reversible, association of the molecule with the plasma membrane. In addition, amentoflavone treatment induced a dose-dependent increase in TMA-DPH fluorescence anisotropy, which could be interpreted as an increase in membrane lipidic order. For apigenin, the effect was much less important. Moreover, exploiting the capacity of TMA-DPH to label endocytic compartments, it was shown that, after association with the membrane, amentoflavone is not internalized into the cell. Possible correlations of these membrane effects with other biological properties are discussed.


Subject(s)
Biflavonoids , Diphenylhexatriene/analogs & derivatives , Flavonoids/metabolism , Fluorescent Dyes , Oils, Volatile/metabolism , Animals , Anisotropy , Cell Line , Cell Membrane/metabolism , Chamomile , Dimerization , Flavonoids/chemistry , Herb-Drug Interactions , Liposomes/metabolism , Mice , Molecular Structure , Oils, Volatile/chemistry , Phospholipids/metabolism , Plants, Medicinal , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...